Omar Keritam
Overview
Explore the profile of Omar Keritam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keritam O, Vincent A, Zimprich F, Cetin H
Front Immunol
. 2024 Dec;
15:1502480.
PMID: 39703505
The discovery of autoantibodies directed against muscle-specific kinase (MuSK) in "seronegative" myasthenia gravis (MG) patients marked a milestone in MG research. In healthy muscle, MuSK regulates a phosphorylation pathway, which...
2.
Clinical heterogeneity within the ALS-FTD spectrum in a family with a homozygous optineurin mutation
Parvizi T, Klotz S, Keritam O, Caliskan H, Imhof S, Konig T, et al.
Ann Clin Transl Neurol
. 2024 May;
11(6):1579-1589.
PMID: 38689506
Objective: Mutations in the gene encoding for optineurin (OPTN) have been reported in the context of different neurodegenerative diseases including the amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) spectrum....
3.
Kleinveld V, Keritam O, Horlings C, Cetin H, Wanschitz J, Hotter A, et al.
Muscle Nerve
. 2024 Feb;
69(4):422-427.
PMID: 38334356
Introduction/aims: The clinical presentation of multifocal motor neuropathy (MMN) may mimic early amyotrophic lateral sclerosis (ALS) with predominant lower motor neuron (LMN) involvement, posing a diagnostic challenge. Both diseases have...
4.
Krenn M, Wagner M, Zulehner G, Weng R, Jager F, Keritam O, et al.
J Neurol
. 2023 Dec;
271(4):1937-1946.
PMID: 38127101
Background: Neuromuscular disorders (NMDs) are heterogeneous conditions with a considerable fraction attributed to monogenic defects. Despite the advancements in genomic medicine, many patients remain without a diagnosis. Here, we investigate...
5.
Ludwig B, Deckert M, Krajnc N, Keritam O, Macher S, Bsteh G, et al.
Eur J Neurol
. 2023 Jun;
30(9):2713-2725.
PMID: 37306533
Background And Purpose: Following increasing demands of patients with suspected neurological symptoms after infection with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the Department of Neurology at the Medical...
6.
Krenn M, Sener M, Rath J, Zulehner G, Keritam O, Wagner M, et al.
J Neurol
. 2022 Oct;
270(2):909-916.
PMID: 36308527
Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders caused by genetic defects resulting in impaired neuromuscular transmission. Although effective treatments are available, CMS is probably underdiagnosed, and...
7.
Keritam O, Juhasz V, Schofer C, Thallinger C, Aretin M, Schabbauer G, et al.
Front Pharmacol
. 2022 Jun;
13:875695.
PMID: 35721106
Extravasation during chemotherapy administration can lead to dangerous adverse effects ranging from pain to tissue necrosis. Evidence-based data about prevention and treatment of extravasation injuries of some clinically used compounds...
8.
Krenn M, Tomschik M, Wagner M, Zulehner G, Weng R, Rath J, et al.
Eur J Neurol
. 2022 Mar;
29(6):1815-1824.
PMID: 35239206
Background And Purpose: Hereditary myopathies with limb-girdle muscular weakness (LGW) are a genetically heterogeneous group of disorders, in which molecular diagnosis remains challenging. Our aim was to present a detailed...
9.
Micko A, Keritam O, Marik W, Strickland B, Briggs R, Shahrestani S, et al.
J Neurosurg
. 2021 Dec;
137(3):609-617.
PMID: 34952511
Objective: Dumbbell-shaped pituitary adenomas (DSPAs) are a subgroup of macroadenomas with suprasellar extension that are characterized by a smaller diameter at the level of the diaphragma sellae opening compared with...
10.
Paternostro R, Staufer K, Traussnigg S, Stattermayer A, Halilbasic E, Keritam O, et al.
Hepatol Int
. 2021 Jun;
15(4):922-933.
PMID: 34076851
Objective: Several single-nucleotide polymorphisms have been identified to be disadvantageous or protective in regard to disease severity in patients with non-alcoholic fatty liver disease (NAFLD). However, it is unclear, whether...